Skip to main content
UniHealth

Doctor search

Alfred Chung, MD

Hematology · San Francisco

NPI 1417375627

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Offices
5
Since medical school
12 years
Northwestern University Feinberg Medical School, 2014

Offices

5 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chung’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A137526 · Current

Licensed to practise in California · since 2015 · expires 2026-11-30 · Northwestern University Feinberg School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Hematology
  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$577,575

Medicare paid this office $577,575 for 240 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)143$43,327$122
Return visit (30+ min)58$6,249$77
New patient visit (60+ min)33$4,796$145
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's157$3,969$15
Biopsy and aspiration of bone marrow sample for diagnosis50$3,665$65
See all 7 services
Every Original Medicare service billed
Long return visit (40+ min)143$43,327$122
Return visit (30+ min)58$6,249$77
New patient visit (60+ min)33$4,796$145
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's157$3,969$15
Biopsy and aspiration of bone marrow sample for diagnosis50$3,665$65
Insertion of needle into vein for collection of blood sample18$796$9
Short return visit (20+ min)12$707$59

Procedures year by year

Procedures billed to Original Medicare by year
Procedure20202021202220232024
Biopsy and aspiration of bone marrow sample for diagnosis––323956

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

240 Original Medicare patients in 2024. Average age 73 · Under 65 9% · 85 and older 7% · Women 46% · Also on Medicaid 23% · Health risk score 2.95. Above the middle of the specialty; the typical hematology clinician is at 2.35.

Conditions among them: High blood pressure 69% · Chronic kidney disease 48% · Heart failure 31% · Coronary heart disease 27% · Diabetes 23% · Atrial fibrillation 21% · Depression 21% · Cancer 16% · COPD 13% · Stroke 9%.

The office billed $4,411,656, Medicare allowed $729,554 and paid $577,575; for 15,480 services of 33 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202424015,480732.95$4,411,656$577,575
20232199,659732.86$2,694,612$366,217
20221912,817722.66$1,034,457$128,588
2021112307732.42$326,281$36,649
20202239732.03$25,832$4,082

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)125$31,574$122
New patient visit (60+ min)54$8,008$148
Return visit (30+ min)44$4,953$77
Biopsy and aspiration of bone marrow sample for diagnosis38$2,653$68

2022: 5 services

Original Medicare services billed in 2022
Long return visit (40+ min)88$30,025$123
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes28$8,599$91
New patient visit (60+ min)57$8,502$149
Return visit (30+ min)29$2,940$74
Biopsy and aspiration of bone marrow sample for diagnosis31$2,183$68

2021: 3 services

Original Medicare services billed in 2021
Long return visit (40+ min)46$17,306$130
New patient visit (60+ min)55$9,018$164
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$6,556$92

Medicaid work

$33,463 in 2024

Medicaid paid $33,463 for 235 billed services this clinician did in 2024, up to 29 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)235$33,463
Medicaid work by year
2024235129$33,463
2023194127$23,800
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)194$23,800

Drugs they prescribed that Part D paid

$4,228,051

Pharmacies billed $4,228,051 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 5% of their Part D prescriptions (28 of 553) in 2024. Above the middle of the specialty; the typical hematology clinician is at 4%.

331 generic and 222 brand-name prescriptions · $4,228,051 in drug cost · 48 antibiotic prescriptions to 18 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Pomalyst105$2,416,126$23,011
Revlimid67$1,326,094$19,792
Lenalidomide11$158,812$14,437
Xarelto15$23,338$1,556
Acyclovir74$1,720$23
See all 10 drugs
Every Part D drug this clinician prescribed
Pomalyst105$2,416,126$23,011
Revlimid67$1,326,094$19,792
Lenalidomide11$158,812$14,437
Xarelto15$23,338$1,556
Acyclovir74$1,720$23
Ondansetron15$1,045$70
Dexamethasone24$342$14
Gabapentin16$290$18
Hydromorphone12$147$12
Sulfamethoxazole-Trimethoprim34$109$3

Year by year

Part D prescribing by year
2024553745% (28)40%$4,228,051
2023511986% (31)None$3,061,716
2022587806% (33)None$2,646,934
202119834None25%$591,499
202029None0% (0)None$48,517
201925None0% (0)None$3,284
201612NoneNoneNone$2,493

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 11 drugs

Part D drugs prescribed in 2023
Pomalyst53$1,256,933$23,716
Revlimid60$1,187,903$19,798
Lenalidomide33$476,172$14,429
Xarelto29$31,330$1,080
Entecavir14$4,918$351
Acyclovir62$2,285$37
Oxycodone12$1,296$108
Ondansetron22$393$18
Sulfamethoxazole-Trimethoprim26$214$8
Gabapentin20$196$10
Dexamethasone19$148$8

2022: 14 drugs

Part D drugs prescribed in 2022
Revlimid74$1,330,528$17,980
Pomalyst45$950,065$21,113
Venclexta11$148,760$13,524
Eliquis28$22,430$801
Atovaquone18$14,652$814
Xarelto14$13,281$949
Entecavir16$5,319$332
Acyclovir102$2,143$21
Dexamethasone30$818$27
Ondansetron17$397$23
Oxycodone20$368$18
Prochlorperazine Maleate11$235$21
Sulfamethoxazole-Trimethoprim42$207$5
Gabapentin16$163$10

2021: 5 drugs

Part D drugs prescribed in 2021
Revlimid30$536,845$17,895
Acyclovir35$962$27
Dexamethasone12$385$32
Ondansetron11$151$14
Sulfamethoxazole-Trimethoprim19$70$4

2019: 1 drug

Part D drugs prescribed in 2019
Acyclovir12$148$12

Money from drug and device companies

$3,174 in 2025

Industry payments by year
202534$2,993$3,174
202422$750$773
202328$4,125$4,292
202111$1,728$1,728

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
E.R. Squibb & Sons L.L.C.None$2,993
1 payment
  • Consulting · 2025-03-24 · $2,993
Legend Biotech USANone$105
1 payment
  • Meals · 2025-03-29 · $105
Janssen BiotechTecvayli$76
2 payments
  • Meals for Tecvayli · 2025-12-05 · $19
  • Meals for Tecvayli · 2025-12-05 · $57
See all 4 published payments
Every published payment
Janssen BiotechMeals · 2025-12-05Tecvayli$19
Janssen BiotechMeals · 2025-12-05Tecvayli$57
Legend Biotech USAMeals · 2025-03-29None$105
E.R. Squibb & Sons L.L.C.Consulting · 2025-03-24None$2,993
See earlier years (2024, 2023, 2021)

2024: $773

Payments by company in 2024
Janssen BiotechDarzalex$750
1 payment
  • Consulting for Darzalex · 2024-03-05 · $750
Genmab U.S.Epkinly$23
1 payment
  • Meals for Epkinly · 2024-02-09 · $23

2023: $4,292

Payments by company in 2023
Janssen BiotechDarzalex$4,264
7 payments
  • Meals for Darzalex · 2023-12-20 · $100
  • Travel for Darzalex · 2023-12-08 · $39
  • Consulting for Darzalex · 2023-12-08 · $1,000
  • Consulting for Darzalex · 2023-11-03 · $750
  • Consulting for Darzalex · 2023-10-13 · $1,125
  • Consulting for Darzalex · 2023-04-11 · $625
  • Consulting for Darzalex · 2023-04-11 · $625
Pharmacyclics LLC An AbbVieEpkinly$28
1 payment
  • Meals for Epkinly · 2023-06-02 · $28

2021: $1,728

Payments by company in 2021
GenzymeSarclisa$1,728
1 payment
  • Consulting for Sarclisa · 2021-10-18 · $1,728

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After Or Refractory To Anti-Bcma Car-T Therapies · 2022Their institution$354,482
Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2024Their institution$257,403
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2023Their institution$223,120
Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2023Their institution$198,068
Celgene Corporation · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025Their institution$160,599
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2024Their institution$158,401
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2024Their institution$137,627
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2025Their institution$128,183
Celgene Corporation · A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma. (Karmma-2) · 2025Their institution$122,301
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2025Their institution$120,579
ABBVIE INC. · A Multicenter Phase 1 Open-Label Dose-Escalation and Expansion Study of Tnb-383b A Bispecific Antibody Targeting Bcma in Subjects With Relapsed Or Refractory Multiple Myeloma · 2025Their institution$104,541
E.R. Squibb & Sons, L.L.C. · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025Their institution$100,092
ABBVIE INC. · A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis · 2024Their institution$77,088
Celgene Corporation · An Efficacy and Safety Study Ofbb2121in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (Karmma-2) · 2024Their institution$65,248
Merck Sharp & Dohme LLC · Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After Or Refractory To Anti-Bcma Car-T Therapies · 2024Their institution$64,433
Janssen Research & Development, LLC · A Phase 2, Open-Label, Randomized Study To Evaluate Prophylactic Interventions on Talquetamab-Related Oral Toxicity · 2025Their institution$57,000
Celgene Corporation · Ct Dual Targeting Bcmaxgprc5d Phase I Esc/Exp Fih/Poc/Reg Study · 2024Their institution$40,464
Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2024Their institution$40,046
Janssen Research & Development, LLC · A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 2025Their institution$35,457
Janssen Research & Development, LLC · A Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Compared With Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2025Their institution$23,708
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients With Stage Iiib Al Cardiac Amyloidosis. · 2023Their institution$23,092
Janssen Research & Development, LLC · Randomized Phase 3 Study To Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezomib and Dexamethasone Cybord Compared To Cybord Alone in Newly Diagnosed Systemic Al Amyloidosis · 2024Their institution$17,902
Janssen Research & Development, LLC · A Multicenter Phase 1/2 Study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis Patients With Translocation (11;14) (Altitude Study) · 2024Their institution$15,907
Celgene Corporation · Phiib Ide-Cel Multi-Cohort Mm (1l, 2l, 4l+) Karmma-2 (Bb2121-Mm-002) - A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clin · 2023Their institution$14,419
Alexion Pharmaceuticals, Inc. · A Phase 3, Double Blind, Multicenter Study To Evaluate the Efficacy and Safety of Cael 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients With Stage Iiia Al Cardiac Amyloidosis. · 2022Their institution$12,115
Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2023Their institution$9,274
Genentech, Inc. · Amyloidosis Rwe Consortium · 2023Their institution$3,144
Celgene Corporation · Phii Ide-Cell Ndmm (Bb2121-Mm-004; Karmma-4) - A Phase 1, Open-Label, Multicenter Study To Evaluate the Safety of Bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (Karmma-4) · 2022Their institution$2,692

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1417375627
Licence
CA A137526California A137526: Current · expires 2026-11-30
Trained
Northwestern University Feinberg Medical School, 2014 · 12 years ago
Group
UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0000X (207RH0000X)
Mailing address
400 Parnassus Ave, San Francisco, CA, 94143
NPI first listed
2014-04-03
NPI last updated
2021-03-03
NPI record certified
2021-03-03

This is when the NPI record was last certified, not a medical board exam.